Buscar
Nektar Therapeutics
NKTRAñadir a la lista de seguimiento
71.040USD
+6.650+10.33%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
2.09BCap. mercado
PérdidaP/E TTM
Más Datos de Nektar Therapeutics Compañía
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Información de Nektar Therapeutics
Símbolo de cotizaciónNKTR
Nombre de la empresaNektar Therapeutics
Fecha de salida a bolsaMay 03, 1994
Director ejecutivoRobin (Howard W)
Número de empleados61
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 03
Dirección455 Mission Bay Boulevard South
CiudadSAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94158
Teléfono18554826587
Sitio Webhttps://www.nektar.com/
Símbolo de cotizaciónNKTR
Fecha de salida a bolsaMay 03, 1994
Director ejecutivoRobin (Howard W)
Ejecutivos de Nektar Therapeutics
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
36.11K
-55.38%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
4.29K
-261.70%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Roy A. Whitfield
Mr. Roy A. Whitfield
Lead Independent Director
Lead Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Mr. Mark A. Wilson, J.D.
Mr. Mark A. Wilson, J.D.
Senior Vice President, Chief Legal Officer
Senior Vice President, Chief Legal Officer
--
--
Dr. Diana M. Brainard, M.D.
Dr. Diana M. Brainard, M.D.
Independent Director
Independent Director
--
--
Ms. Sandra A. Gardiner
Ms. Sandra A. Gardiner
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Corey Davis
Mr. Corey Davis
Managing Director
Managing Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
36.11K
-55.38%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
4.29K
-261.70%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Roy A. Whitfield
Mr. Roy A. Whitfield
Lead Independent Director
Lead Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Nektar Therapeutics?
Los cinco principales accionistas de Nektar Therapeutics son: Mr. Howard W. Robin
¿Cuántas instituciones poseen acciones de Nektar Therapeutics (NKTR)?
A fecha de 2026Q1, 437 instituciones poseen acciones de Nektar Therapeutics, con un valor de mercado combinado de aproximadamente 20.71M, lo que representa el 61.39% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 1322059.00.